Pfizer Inc said on Thursday its vaccine for Respiratory Syncytial Virus (RSV) was effective among older adults in a late-stage study and it plans to file for approval with the U.S. health regulator in the coming months.
Pfizer's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustrationsaid on Thursday its vaccine for Respiratory Syncytial Virus was effective among older adults in a late-stage study and it plans to file for approval with the U.S. health regulator in the coming months.
There are no U.S. approved vaccines for RSV, a common virus that typically causes mild cold-like symptoms but can be fatal for young kids and older adults. RSV is estimated to cause about 14,000 annual deaths among older adults in the United States. Pfizer's vaccine was 85.7% effective among participants with three or more symptoms, and 66.7% for two or more symptoms, according to an interim analysis carried out by an external data monitoring panel.The vaccine, RSVpreF, was also found to be well-tolerated with no safety concerns in the study.
Pfizer's shot is designed to target two strains of the respiratory virus. The company has so far enrolled about 37,000 participants aged 60 and above in its late-stage global study of the vaccine.Pfizer said it also plans to prepare submissions for approval of the shot to other regulatory authorities in the coming months.Reporting by Amruta Khandekar; Editing by Shinjini Ganguli
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer COVID shots appear 73% effective in children under 5Only about 6% of youngsters ages 6 months through 4 years had gotten at least one dose of a COVID-19 vaccine.
Read more »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Read more »
Pfizer COVID shots appear 73% effective in children under 5Only about 6% of youngsters ages 6 months through 4 years had gotten at least one dose of a COVID-19 vaccine.
Read more »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Read more »
Pfizer COVID shots appear 73% effective in children under 5Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring.
Read more »